Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRMYNASDAQ:ROIVNASDAQ:RVMDNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$32.48+0.0%$32.47$26.47▼$41.61$1.86B0.87626,648 shs422,843 shsROIVRoivant Sciences$11.44+3.0%$10.90$8.73▼$13.06$7.55B1.165.63 million shs7.92 million shsRVMDRevolution Medicines$39.93+2.0%$39.20$29.17▼$62.40$7.29B1.11.54 million shs3.02 million shsVRNAVerona Pharma PLC American Depositary Share$90.92-2.2%$73.21$14.14▼$94.45$7.91B0.211.32 million shs1.01 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences+0.03%-7.57%-9.55%-6.93%+12.43%ROIVRoivant Sciences+2.97%+1.42%+5.54%+4.28%+5.54%RVMDRevolution Medicines+2.02%-2.11%0.00%+3.74%+5.86%VRNAVerona Pharma PLC American Depositary Share-2.16%+0.97%+25.27%+37.20%+486.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHRMYHarmony Biosciences4.7844 of 5 stars4.61.00.00.03.53.34.4ROIVRoivant Sciences1.8993 of 5 stars3.53.00.00.00.02.50.0RVMDRevolution Medicines4.342 of 5 stars4.51.00.04.73.11.70.0VRNAVerona Pharma PLC American Depositary Share2.1838 of 5 stars2.63.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRMYHarmony Biosciences 3.11Buy$53.0063.18% UpsideROIVRoivant Sciences 3.00Buy$17.5052.97% UpsideRVMDRevolution Medicines 3.00Buy$67.0868.00% UpsideVRNAVerona Pharma PLC American Depositary Share 3.00Buy$91.110.21% UpsideCurrent Analyst Ratings BreakdownLatest HRMY, ROIV, VRNA, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.006/18/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.00 ➝ $116.006/11/2025VRNAVerona Pharma PLC American Depositary ShareCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.006/11/2025VRNAVerona Pharma PLC American Depositary ShareJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$95.00 ➝ $110.006/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.006/2/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRMYHarmony Biosciences$714.73M2.61$2.95 per share11.02$11.56 per share2.81ROIVRoivant Sciences$29.05M267.71N/AN/A$7.45 per share1.54RVMDRevolution Medicines$11.58M642.29N/AN/A$13.47 per share2.96VRNAVerona Pharma PLC American Depositary Share$42.28M183.07N/AN/A$2.56 per share35.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRMYHarmony Biosciences$145.49M$2.6212.4010.440.4820.53%24.32%15.92%8/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,030.67N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest HRMY, ROIV, VRNA, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRMYHarmony BiosciencesN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRMYHarmony Biosciences0.223.673.63ROIVRoivant SciencesN/A33.4733.47RVMDRevolution MedicinesN/A13.4613.46VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRMYHarmony Biosciences86.23%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipHRMYHarmony Biosciences23.60%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableROIVRoivant Sciences860679.81 million626.10 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableHRMY, ROIV, VRNA, and RVMD HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in StockJune 18 at 5:56 PM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth CapitalJune 18 at 1:02 PM | marketbeat.comTraders Purchase Large Volume of Verona Pharma Put Options (NASDAQ:VRNA)June 17 at 2:31 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?June 16 at 5:48 PM | marketbeat.comTraders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)June 16 at 11:56 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 400,000 SharesJune 16 at 4:19 AM | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in StockJune 16 at 4:19 AM | americanbankingnews.comJefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre LaunchJune 14, 2025 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 14, 2025 | insidertrades.comCantor Fitzgerald Predicts Verona Pharma FY2025 EarningsJune 14, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 13, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 SharesJune 13, 2025 | marketbeat.comJefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre LaunchJune 13, 2025 | insidermonkey.comCantor Fitzgerald Estimates Verona Pharma FY2025 EarningsJune 13, 2025 | marketbeat.comCantor Fitzgerald Comments on Verona Pharma FY2026 EarningsJune 13, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock PriceJune 13, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Trading Up 4.5% on Analyst UpgradeJune 13, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $110.00 at Jefferies Financial GroupJune 12, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Shares Up 4.5% on Analyst UpgradeJune 11, 2025 | marketbeat.comJefferies Financial Group Issues Positive Forecast for Verona Pharma (NASDAQ:VRNA) Stock PriceJune 11, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Expected to Rise, Cantor Fitzgerald Analyst SaysJune 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, ROIV, VRNA, and RVMD Company DescriptionsHarmony Biosciences NASDAQ:HRMY$32.48 +0.01 (+0.03%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$32.48 0.00 (-0.02%) As of 06/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Roivant Sciences NASDAQ:ROIV$11.44 +0.33 (+2.97%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$11.44 0.00 (0.00%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$39.93 +0.79 (+2.02%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$40.17 +0.24 (+0.61%) As of 06/18/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$90.92 -2.01 (-2.16%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$91.06 +0.14 (+0.15%) As of 06/18/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
